PROBIOCON GMBH has a total of 12 patent applications. It decreased the IP activity by 100.0%. Its first patent ever was published in 2015. It filed its patents most often in Canada, China and EPO (European Patent Office). Its main competitors in its focus markets pharmaceuticals, biotechnology and measurement are GANYMED PHARMACEUTICALS AG, CHINA SYNTHETIC RUBBER CORP and AGENSYS INC.
# | Country | Total Patents | |
---|---|---|---|
#1 | Canada | 2 | |
#2 | China | 2 | |
#3 | EPO (European Patent Office) | 2 | |
#4 | Republic of Korea | 2 | |
#5 | United States | 2 | |
#6 | WIPO (World Intellectual Property Organization) | 2 |
# | Industry | |
---|---|---|
#1 | Pharmaceuticals | |
#2 | Biotechnology | |
#3 | Measurement |
# | Technology | |
---|---|---|
#1 | Peptides | |
#2 | Therapeutic chemical compounds | |
#3 | Medical preparations | |
#4 | Analysing materials | |
#5 | Measuring microorganism processes |
# | Name | Total Patents |
---|---|---|
#1 | Herrmann Andreas | 12 |
#2 | Salih Helmut | 12 |
#3 | Maurer Stefanie | 8 |
#4 | Schmied Bastian Julius | 6 |
#5 | Grosse-Hovest Ludger | 4 |
#6 | Raab Stefanie | 4 |
#7 | Kopp Hans-Georg | 4 |
#8 | Grosse Hovest Ludger | 2 |
#9 | Kopp Hans Georg | 2 |
Publication | Filing date | Title |
---|---|---|
KR20190030646A | Anticancer combination treatment | |
KR20170103767A | Rankl-specific agent for treating metastatic disease |